Взаимодействия с лекарствами
What laboratory studies, small human studies and case reports actually show about kava interactions.
Содержание
Премиум Нобл Кава
Откройте для себя сертифицированное качество и чистоту у нашего официального партнера.
На Kava-mode.comКратко и по делу
Kava can interact with medicines and other central nervous system depressants. Laboratory findings show several possible CYP inhibitions, but small human studies do not confirm one uniform pattern across all enzymes. Alcohol and sedatives in particular should not be self-combined; regular medication warrants individual review.
- ●Алкоголь – Additive drowsiness and impaired coordination are possible; concurrent use is not recommended
- ●Бензодиазепинами – Possible additive CNS depression; combine only after professional review
- ●Антипсихотиками – Sedation and pharmacokinetic interactions are possible; direct clinical data are limited
- ●Антикоагулянтами – Controlled interaction data are lacking; the narrow therapeutic window requires medical review
Система цитохрома P450
Система цитохрома P450 (CYP450) представляет собой семью ферментов в печени, отвечающих за метаболизм большинства лекарств. Когда вещество ингибирует эти ферменты, другие вещества метаболизируются медленнее – их действие и побочные эффекты могут усиливаться.
Почему это важно?
Many medicines are metabolised by CYP enzymes. An in-vitro finding does not automatically mean clinically relevant inhibition in humans. Preparation, dose, duration and the medicine's therapeutic window determine practical relevance.
Какие ферменты ингибируются?
Mathews et al. (2002) tested kava extract and individual kavalactones in human liver microsomes and found inhibition of several CYP enzymes. These are in-vitro findings, not clinical inhibition ratings in humans:
| Фермент | Сила ингибирования | Важные субстраты (примеры) |
|---|---|---|
| CYP1A2 | In-vitro finding | Кофеин, Теофиллин, Клозапин, Оланзапин |
| CYP2C9 | In-vitro finding | Варфарин, Фенитоин, НПВП (Ибупрофен) |
| CYP2C19 | In-vitro finding | Омепразол, Диазепам, Клопидогрел |
| CYP2D6 | In-vitro finding | Кодеин, Трамадол, многие антидепрессанты |
| CYP3A4 | In-vitro finding | Бензодиазепины, Статины, многие антибиотики |
Клиническое значение
Russmann et al. (2005) reported reduced CYP1A2 activity in chronic users of traditional aqueous kava. Gurley et al. (2005; 12 healthy volunteers, 28 days, 138 mg kavalactones/day), by contrast, found reduced CYP2E1 but no significant change in CYP1A2, CYP2D6 or CYP3A4/5. The human findings are small and preparation- and consumption-dependent, so they cannot predict every medicine interaction.
Комбинации с высоким риском
The following combinations should be avoided or medically reviewed in advance. Reasons differ: some involve additive CNS effects or case reports, while others have only mechanistic signals and no controlled combination trials.
⚠ Алкоголь
Risiko: AVOID
Concurrent use of kava and alcohol is not recommended:
- 1.Additive CNS effects: Drowsiness, slower reactions and impaired coordination may increase.
- 2.Liver risk not quantified: A combined liver risk has not been quantified reliably; the combination is avoided because of this uncertainty.
- 3.Unpredictable intensity: Product, amount, drinking pattern and individual sensitivity make effects difficult to predict.
Do not use kava and alcohol together. The main practical reason is possible additive impairment of attention, reaction and coordination; the size of any additional liver risk is not reliably established.
⚠ Бензодиазепины и снотворные
Risiko: PROFESSIONAL REVIEW
Do not combine benzodiazepines or Z-drugs with kava without medical review:
- •Additive sedation: Drowsiness and psychomotor impairment may increase.
- •CNS depression: Clinically relevant potentiation is possible; controlled combination trials are lacking.
- •Interpret CYP findings: CYP3A4 inhibition was observed in vitro but not consistently confirmed in small human studies.
Кейс: Almeida & Grimsley (1996) described a semicomatose state in a 54-year-old man after reported kava and alprazolam use. A single case report is a warning signal but does not establish mechanism or frequency.
⚠ Антипсихотики
Risiko: PROFESSIONAL REVIEW
Individual medical review is appropriate before kava use with antipsychotics:
- •Sedation: Additive drowsiness or psychomotor impairment is possible.
- •Case reports: Individual reports describe movement disorders; frequency and causality are unclear.
- •CYP findings: Laboratory inhibition does not reliably predict the level of a specific medicine.
⚠ Антикоагулянты (разжижающие кровь)
Risiko: PROFESSIONAL REVIEW
Warfarin, phenprocoumon and other anticoagulants require professional review because of their narrow therapeutic window:
- •Mechanistic signal: CYP2C9 inhibition was observed in vitro; a clinical kava-warfarin interaction has not been established in controlled studies.
- •Monitor INR: Changes in co-used products should be coordinated with the treating clinician.
- •Bleeding risk: The baseline risk of anticoagulation makes self-testing inappropriate.
Use kava with anticoagulation only after individual medical review.
Комбинации с умеренным риском
Следующие комбинации требуют осторожности и должны проводиться только после консультации с врачом. Может потребоваться корректировка дозы.
Антидепрессанты
Risiko: PROFESSIONAL REVIEW
- • Pharmacokinetic interactions may occur depending on the product but are not clinically established as a class
- • Serotonin syndrome from kava is not established as a typical clinical effect
- • Additive drowsiness or dizziness are possible
- • Direct clinical combination data are limited
- • Review co-medication individually rather than inferring from in-vitro CYP data
- • MAO-B effects of individual kavalactones have been studied preclinically
- • Pawa et al. (2026) found MAO-A inhibition by flavokawain A in an in-vitro enzyme assay; humans and combination with MAO inhibitors were not studied
- • Do not self-combine with MAO inhibitors because medicine interactions can be serious
- • Obtain medical review before use
Противоэпилептические средства
Risiko: PROFESSIONAL REVIEW
Фенитоин, Карбамазепин, Вальпроат и другие противоэпилептические средства:
- •Pharmacokinetics: Altered levels are possible but cannot be predicted reliably for individual combinations.
- •CNS effects: Additive drowsiness or coordination problems are possible.
- •Seizure control: Changes in co-used products belong under professional supervision.
При эпилепсии Кава должна использоваться только под медицинским наблюдением.
Лекарства при болезни Паркинсона
Risiko: PROFESSIONAL REVIEW
Леводопа и дофаминовые агонисты:
- •Mechanism unclear: Blanket clinical dopamine antagonism by kava has not been established.
- •Case reports: Individual reports describe worsening Parkinson symptoms; medical review is therefore needed.
With Parkinson's disease or related medication, use kava only after medical review.
Гепатотоксичные препараты
Risiko: УМЕРЕННЫЙ
Препараты с известным гепатотоксичным потенциалом:
- •Парацетамол/Ацетаминофен: Особенно проблематично при высоких дозах
- •Статины: Аторвастатин, Симвастатин и др. (субстраты CYP3A4)
- •Метотрексат: Иммунодепрессант с гепатотоксичностью
- •Изониазид: Препарат против туберкулеза
Additional liver risk is plausible but not quantified for every combination. Potentially hepatotoxic medication requires individual medical review.
Обзорная таблица взаимодействий
| Класс вещества | Примеры | Риск | Механизм |
|---|---|---|---|
| Алкоголь | Этанол | AVOID | Possible additive sedation and impaired coordination; liver risk not quantified |
| Бензодиазепины | Диазепам, Лоразепам, Алпразолам | PROFESSIONAL REVIEW | Possible additive CNS depression; one case report, no controlled combination trials |
| Антипсихотики | Галоперидол, Оланзапин, Клозапин | PROFESSIONAL REVIEW | Sedation or interactions possible; direct clinical data limited |
| Антикоагулянты | Варфарин, Фенпрокумон | PROFESSIONAL REVIEW | No controlled kava interaction established; narrow therapeutic window |
| СИОЗС | Флуоксетин, Сертралин, Пароксетин | PROFESSIONAL REVIEW | Possible sedation or pharmacokinetics; no established kava serotonin syndrome |
| Противоэпилептические средства | Фенитоин, Карбамазепин | PROFESSIONAL REVIEW | Possible additive CNS effects and unpredictable pharmacokinetics |
| Лекарства при болезни Паркинсона | Леводопа, дофаминовые агонисты | PROFESSIONAL REVIEW | Case reports of symptom worsening; no blanket dopamine antagonism established |
| Статины | Аторвастатин, Симвастатин | PROFESSIONAL REVIEW | Direct clinical interaction data are lacking; review liver and medication context |
| Опioиды | Кодеин, Трамадол, Морфин | AVOID / REVIEW | Possible additive CNS depression |
| Кофеин | Кофе, энергетические напитки | CAUTION | Human CYP1A2 findings are small and inconsistent |
Практические рекомендации
Контрольный список перед потреблением Кавы
- 1.Проверить список лекарств
Проверить все текущие лекарства на взаимодействия
- 2.Консультация с врачом
При регулярном приеме лекарств получить медицинский совет перед потреблением Кавы
- 3.Избегать алкоголя
Do not use kava and alcohol together. The main practical reason is possible additive impairment of attention, reaction and coordination; the size of any additional liver risk is not reliably established.
- 4.Низкая доза
Do not experiment with a self-selected lower kava dose while taking medicines; obtain professional review of the combination.
- 5.Наблюдать за симптомами
Обращать внимание на необычную усталость, головокружение или другие симптомы
Продолжить в разделе Безопасность
На основе исследований
С вкладом от
Это вики - это курируемый ресурс, который синтезирует исследования из рецензируемых исследований и экспертных исследователей. Он не был написан исследователями, перечисленными выше, а скорее основан на их опубликованных работах.
Научные источники
Информация на этой странице основана на следующих научных исследованиях и публикациях:
Cytochrome P450 2E1 (CYP2E1) Is the Principal Enzyme Responsible for Urethane Metabolism
Hoffler U., El-Masri H.A., Ghanayem B.I. (2003) – Journal of Pharmacology and Experimental Therapeutics
Посмотреть исследованиеKava: From Ethnology to Pharmacology
Yadhu N. Singh (Editor) (2004) – CRC Press
Посмотреть исследованиеСодержание
Премиум Нобл Кава
Откройте для себя сертифицированное качество и чистоту у нашего официального партнера.
На Kava-mode.com
Кава – корень спокойствия
Полное руководство по действию, истории и культуре.